ince 1990, we have been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment.
Always seeking to be at the forefront of product innovation, we entered the interventional cardiology market in 2000 with our proprietary coronary stent and accompanying stent delivery system.
Since that time, Biosensors has rapidly grown to become the world’s fourth largest supplier of cardiac stents, with the BioMatrix™ family of drug-eluting stent and the Axxess™ self-expanding bifurcation stent. Our pioneering work has continued with the development of the BioFreedom drug-coated stent, which received CE Mark approval in January 2013 and is currently available in selected markets.
In 2013, we have expanded our reach with the Spectrum Dynamics acquisition and our D-SPECT system is a cardiology-dedicated nuclear imaging system used by leading medical centers around the world. D-SPECT aims to help physicians select the right patients for percutaneous coronary intervention (PCI)
In 2015 we have also recently entered the endovascular therapy area with both a specific drug-eluting stent based on our proprietary BioMatrix technology and drug-eluting balloons for both below and above the knee interventions.